Calamos Advisors LLC Acquires 23,371 Shares of Stryker Co. (NYSE:SYK)

Calamos Advisors LLC grew its holdings in shares of Stryker Co. (NYSE:SYK) by 34.1% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 91,852 shares of the medical technology company’s stock after acquiring an additional 23,371 shares during the period. Calamos Advisors LLC’s holdings in Stryker were worth $27,506,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the business. Vanguard Group Inc. raised its stake in shares of Stryker by 0.5% during the third quarter. Vanguard Group Inc. now owns 30,665,520 shares of the medical technology company’s stock valued at $8,379,967,000 after acquiring an additional 143,631 shares during the last quarter. Morgan Stanley raised its stake in Stryker by 21.7% during the fourth quarter. Morgan Stanley now owns 5,978,782 shares of the medical technology company’s stock worth $1,461,753,000 after buying an additional 1,066,751 shares during the last quarter. FMR LLC grew its holdings in Stryker by 2.5% in the third quarter. FMR LLC now owns 5,972,582 shares of the medical technology company’s stock worth $1,632,127,000 after purchasing an additional 144,208 shares during the period. Geode Capital Management LLC grew its holdings in Stryker by 2.0% in the first quarter. Geode Capital Management LLC now owns 5,954,038 shares of the medical technology company’s stock worth $1,695,169,000 after purchasing an additional 117,786 shares during the period. Finally, Northern Trust Corp grew its holdings in Stryker by 3.9% in the third quarter. Northern Trust Corp now owns 3,505,595 shares of the medical technology company’s stock worth $957,974,000 after purchasing an additional 131,590 shares during the period. Institutional investors own 77.09% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on SYK. Canaccord Genuity Group upgraded shares of Stryker from a “hold” rating to a “buy” rating and raised their price target for the stock from $315.00 to $360.00 in a report on Wednesday, January 31st. Roth Mkm raised their price target on shares of Stryker from $345.00 to $348.00 and gave the stock a “buy” rating in a report on Wednesday, January 31st. Canaccord Genuity Group upgraded shares of Stryker from a “hold” rating to a “buy” rating and set a $360.00 price objective for the company in a report on Wednesday, January 31st. Wells Fargo & Company lifted their price objective on shares of Stryker from $336.00 to $364.00 and gave the company an “overweight” rating in a report on Wednesday, January 31st. Finally, Truist Financial lifted their price objective on shares of Stryker from $330.00 to $345.00 and gave the company a “hold” rating in a report on Wednesday, January 31st. Three analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and a consensus price target of $340.45.

Insiders Place Their Bets

In other news, Director Allan C. Golston sold 3,273 shares of the business’s stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total value of $1,116,093.00. Following the sale, the director now owns 14,242 shares of the company’s stock, valued at $4,856,522. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, Director Ronda E. Stryker sold 201,146 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $342.90, for a total value of $68,972,963.40. Following the sale, the director now owns 3,755,128 shares of the company’s stock, valued at $1,287,633,391.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Allan C. Golston sold 3,273 shares of the business’s stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the completion of the sale, the director now directly owns 14,242 shares in the company, valued at approximately $4,856,522. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 212,109 shares of company stock valued at $72,845,768. Company insiders own 5.90% of the company’s stock.

Stryker Stock Performance

SYK stock traded up $1.44 during mid-day trading on Friday, hitting $328.89. The company had a trading volume of 200,582 shares, compared to its average volume of 1,249,636. The firm has a market cap of $125.13 billion, a PE ratio of 39.69, a price-to-earnings-growth ratio of 2.71 and a beta of 0.89. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.97 and a current ratio of 1.58. Stryker Co. has a 12 month low of $249.98 and a 12 month high of $361.41. The stock’s fifty day moving average price is $350.34 and its two-hundred day moving average price is $312.14.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $3.46 EPS for the quarter, topping the consensus estimate of $3.27 by $0.19. The business had revenue of $5.82 billion for the quarter, compared to analyst estimates of $5.60 billion. Stryker had a net margin of 15.44% and a return on equity of 22.99%. The company’s revenue for the quarter was up 11.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.00 earnings per share. On average, analysts forecast that Stryker Co. will post 11.86 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be given a $0.80 dividend. This represents a $3.20 annualized dividend and a yield of 0.97%. The ex-dividend date of this dividend is Wednesday, March 27th. Stryker’s dividend payout ratio is 38.79%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.